230 related articles for article (PubMed ID: 9893967)
1. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa.
Schense JC; Hubbell JA
Bioconjug Chem; 1999; 10(1):75-81. PubMed ID: 9893967
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension.
Schense JC; Bloch J; Aebischer P; Hubbell JA
Nat Biotechnol; 2000 Apr; 18(4):415-9. PubMed ID: 10748522
[TBL] [Abstract][Full Text] [Related]
3. Crosslinking kinetics of the human transglutaminase, factor XIII[A2], acting on fibrin gels and gamma-chain peptides.
Lewis KB; Teller DC; Fry J; Lasser GW; Bishop PD
Biochemistry; 1997 Feb; 36(5):995-1002. PubMed ID: 9033388
[TBL] [Abstract][Full Text] [Related]
4. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury.
Taylor SJ; McDonald JW; Sakiyama-Elbert SE
J Control Release; 2004 Aug; 98(2):281-94. PubMed ID: 15262419
[TBL] [Abstract][Full Text] [Related]
5. Staphylococcus aureus fibronectin-binding protein serves as a substrate for coagulation factor XIIIa: evidence for factor XIIIa-catalyzed covalent cross-linking to fibronectin and fibrin.
Matsuka YV; Anderson ET; Milner-Fish T; Ooi P; Baker S
Biochemistry; 2003 Dec; 42(49):14643-52. PubMed ID: 14661977
[TBL] [Abstract][Full Text] [Related]
6. Factor XIIIa-derived peptides inhibit transglutaminase activity. Localization of substrate recognition sites.
Achyuthan KE; Slaughter TF; Santiago MA; Enghild JJ; Greenberg CS
J Biol Chem; 1993 Oct; 268(28):21284-92. PubMed ID: 8104938
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic evaluation of factor XIIIa*-like enzyme activity in equine plasma as a potential therapeutic avenue for the inhibition of fibrinous tissue.
Coyne CP; Smith JE; DeBowes RM
Am J Vet Res; 1992 May; 53(5):695-705. PubMed ID: 1355954
[TBL] [Abstract][Full Text] [Related]
8. Release rate controls biological activity of nerve growth factor released from fibrin matrices containing affinity-based delivery systems.
Wood MD; Sakiyama-Elbert SE
J Biomed Mater Res A; 2008 Feb; 84(2):300-12. PubMed ID: 17607752
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering.
Sakiyama SE; Schense JC; Hubbell JA
FASEB J; 1999 Dec; 13(15):2214-24. PubMed ID: 10593869
[TBL] [Abstract][Full Text] [Related]
10. Contact with the N termini in the central E domain enhances the reactivities of the distal D domains of fibrin to factor XIIIa.
Samokhin GP; Lorand L
J Biol Chem; 1995 Sep; 270(37):21827-32. PubMed ID: 7665605
[TBL] [Abstract][Full Text] [Related]
11. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen.
Matsuka YV; Medved LV; Migliorini MM; Ingham KC
Biochemistry; 1996 May; 35(18):5810-6. PubMed ID: 8639541
[TBL] [Abstract][Full Text] [Related]
12. Identification of the alpha chain lysine donor sites involved in factor XIIIa fibrin cross-linking.
Sobel JH; Gawinowicz MA
J Biol Chem; 1996 Aug; 271(32):19288-97. PubMed ID: 8702612
[TBL] [Abstract][Full Text] [Related]
13. Controlled release of glial-derived neurotrophic factor from fibrin matrices containing an affinity-based delivery system.
Wood MD; Borschel GH; Sakiyama-Elbert SE
J Biomed Mater Res A; 2009 Jun; 89(4):909-18. PubMed ID: 18465825
[TBL] [Abstract][Full Text] [Related]
14. The covalent structure of factor XIIIa crosslinked fibrinogen fibrils.
Mosesson MW; Siebenlist KR; Hainfeld JF; Wall JS
J Struct Biol; 1995; 115(1):88-101. PubMed ID: 7577232
[TBL] [Abstract][Full Text] [Related]
15. Neurite extension and in vitro myelination within three-dimensional modified fibrin matrices.
Pittier R; Sauthier F; Hubbell JA; Hall H
J Neurobiol; 2005 Apr; 63(1):1-14. PubMed ID: 15616962
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional migration of neurites is mediated by adhesion site density and affinity.
Schense JC; Hubbell JA
J Biol Chem; 2000 Mar; 275(10):6813-8. PubMed ID: 10702239
[TBL] [Abstract][Full Text] [Related]
17. Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices.
Willerth SM; Johnson PJ; Maxwell DJ; Parsons SR; Doukas ME; Sakiyama-Elbert SE
J Biomed Mater Res A; 2007 Jan; 80(1):13-23. PubMed ID: 16958043
[TBL] [Abstract][Full Text] [Related]
18. Development of fibrin derivatives for controlled release of heparin-binding growth factors.
Sakiyama-Elbert SE; Hubbell JA
J Control Release; 2000 Apr; 65(3):389-402. PubMed ID: 10699297
[TBL] [Abstract][Full Text] [Related]
19. Rheological characterization and dissolution kinetics of fibrin gels crosslinked by a microbial transglutaminase.
Sun Y; Giraudier O; Garde VL
Biopolymers; 2005 Apr; 77(5):257-63. PubMed ID: 15700298
[TBL] [Abstract][Full Text] [Related]
20. Tailored laminin-332 alpha3 sequence is tethered through an enzymatic linker to a collagen scaffold to promote cellular adhesion.
Damodaran G; Collighan R; Griffin M; Navsaria H; Pandit A
Acta Biomater; 2009 Sep; 5(7):2441-50. PubMed ID: 19364681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
